PRESS RELEASES

Date	Title
Apr 18, 2023	Ardelyx Resubmits New Drug Application to U.S. Food and Drug Administration for XPHOZAH® (tenapanor)
Apr 13, 2023	Ardelyx, Inc. Reports Employment Inducement Grants
Apr 12, 2023	Ardelyx Presents Positive Data Further Supporting Efficacy and Safety of XPHOZAH® (tenapanor) at National Kidney Foundation 2023 Spring Clinical Meetings
Mar 2, 2023	Ardelyx Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Feb 28, 2023	Ardelyx Publishes First Environmental, Social and Governance (ESG) Report
Feb 27, 2023	Ardelyx to Participate at the Cowen 43rd Annual Health Care Conference
Feb 23, 2023	Ardelyx to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 2, 2023
Feb 2, 2023	Ardelyx, Inc. Reports Employment Inducement Grants
Dec 29, 2022	FDA Grants Appeal for Ardelyx's XPHOZAH® (tenapanor)
Dec 23, 2022	Ardelyx, Inc. Reports Employment Inducement Grants

FAQs

Email Alerts

Connect

Bay Area
34175 Ardenwood Boulevard
Fremont, CA 94555

Greater Boston
400 Fifth Avenue, Suite 210
Waltham, MA 02451

Phone: 617.675.ARDX (2739)

Inquiries:
General: info@ardelyx.com
Media: media@ardelyx.com
Investor: investor@ardelyx.com
Business Development: partnering@ardelyx.com